Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Summary

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)

Timeline

Start

2019-09-23

Primary completion

2023-09-15

Completion

2023-09-15

Publications

• Jacoby J, Mahalingam D, Alistar A, Garmey E, Kazmi S, Mooneyham T, Sun L, Yap TA, Vu P, Moser J. Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies. J Immunother Cancer. 2025 Jun 18;13(6):e011572. doi: 10.1136/jitc-2025-011572.

Drugs

Indications